Company Overview and News

0
Strong Technical And Fundamental Basis For SORL Price Breakout

2018-08-17 seekingalpha
Recent Q2 Earnings Surprise with 40% sales growth and record quarterly revenue to $128.5 million will send price higher.
CAAS CPS SORL BWA COSHW

0
BWA / BorgWarner, Inc. FORM 8-K BORGWARNER INC. 8-16-2018 (Current Report)

2018-08-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BWA

0
BorgWarner Doing Its Part, But Sentiment Remains Weak

2018-08-03 seekingalpha
BorgWarner continues to deliver good organic growth on the back of growing efficiency-driven vehicle content, but the Street is down on the sector right now.
BWA

14
Auto suppliers retool to chase electric vehicle bonanza - Channel NewsAsia

2018-08-01 channelnewsasia
In what seems to be a magic trick, Dele Fayemi runs a batch of batteries in a beaker of boiling water - a physical impossibility that should cause a short circuit.
MTSI NHYKF NHYDY BWA NHY TEL GM

14
Auto suppliers retool to chase electric vehicle bonanza

2018-08-01 reuters
ST. PAUL, Minn. (Reuters) - In what seems to be a magic trick, Dele Fayemi runs a batch of batteries in a beaker of boiling water - a physical impossibility that should cause a short circuit.
MTSI NHYKF NHYDY BWA NHY TEL GM

8
Auto Stocks' Earnings Roster for Aug 1: TSLA, RACE & More

2018-07-31 zacks
Several Auto companies, including some big players, have already released their earnings in the past week. In the last couple of days, BorgWarner Inc. (BWA - Free Report) and The Goodyear Tire & Rubber Company (GT - Free Report) reported an earnings beat for the second quarter. A few important companies, which are slated to announce their quarterly numbers on Aug 1, are Tesla, Inc. (TSLA - Free Report) , Ferrari N.
FOXF CWH AMKR BWA MTOR EMES

0
BWA / BorgWarner, Inc. null (Current Report)

2018-07-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
BWA

10
BorgWarner (BWA) Q2 2018 Results - Earnings Call Transcript

2018-07-26 seekingalpha
Good morning. My name is Tasha and I will be your conference facilitator. At this time, I would like to welcome everyone to the BorgWarner 2018 Second Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers remarks there will be a question-and-answer period.
WFCNP SEVAP MS WFC BWA SEV

0
BWA / BorgWarner, Inc. 10-Q (Quarterly Report)

2018-07-26 sec.gov
Document Table of Contents
BWA

6
BorgWarner's (BWA) Q2 Earnings Beat Estimates, Revenues Miss

2018-07-26 zacks
BorgWarner Inc. (BWA - Free Report) delivered adjusted earnings of $1.18 per share in second-quarter 2018, beating the Zacks Consensus Estimate of $1.10. The figure also increased from 96 cents per share in the year-ago quarter. Net earnings rose to $272 million from the prior-year quarter figure of $212 million.
FOXF OSK DRE SEVAP BWA LAD SEV

6
BorgWarner's (BWA) Q2 Earnings Surpass Estimates, Gains Y/Y

2018-07-26 zacks
BorgWarner Inc. (BWA - Free Report) offers efficient and clean technology solutions, essential for combustion, hybrid and electric vehicles.
7018 CME SEVAP BWA SEV

0
BWA / BorgWarner, Inc. 8-K (Current Report)

2018-07-26 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BWA

3
Auto Stocks' Q2 Earnings Roster for Jul 26: BWA, LKQ & More

2018-07-25 zacks
The second-quarter earnings season is in full swing. Within the Auto sector, a few have already released their earnings while a majority of them will report in the next few days. On Jul 24, PACCAR Inc. (PCAR - Free Report) and Harley-Davidson Inc. (HOG - Free Report) reported an earnings beat in the second quarter.
VC LEA BWA PCAR HOG LKQ

0
What's in Store for BorgWarner (BWA) This Earnings Season?

2018-07-23 zacks
BorgWarner Inc. (BWA - Free Report) is set to release second-quarter 2018 earnings on Jul 26, before the market opens. In the last reported quarter, the company delivered a positive earnings surprise of 6.8%. It surpassed expectations in all the trailing four quarters, with an average beat of 7.2%.
CMQMY OSK AXL BWA CMI

26
Top Analyst Upgrades and Downgrades: Avon, Broadcom, CDW, CSX, Goldman Sachs, Starbucks, Twitter, Under Armour, Windstream and More

2018-07-18 247wallst - 1
Stocks were looking for direction on Wednesday with a fairly light day on economic data. Investors have had less faith and have seen lower rewards from buying the dips than in prior years. Many of those same investors have also been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and also for the longer term, into 2019 and beyond.
WFCNP UAA COLM AVP CDW EXR FPI BMO TWTR AVGO CF CDWHF CSX WFC BMO UA BWA FHN TRI SBUX BRCM

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 099724106